Jamie Ketas - Concepedia

Author

Jamie Ketas

Also Known As

J. C. Ketas, Jamie C Ketas, Jamie C. Ketas, Jamie Ketas

Publications

742

Citations

H-Index

Concepts

All Affiliations

Jamie Ketas is an author at Cornell University specializing in allergy, immunology, and tumor biology.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	47
2	Allergy	1	1	47
3	Immunology	1	1	47
4	Autoimmunity	1	1	47
5	Immunotherapy	1	1	47

Jamie Ketas

Publications

741

Citations

H-Index

Page 1

	Year	Citations
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma John P. Leonard, Morton Coleman, Jamie Ketas, Journal of Clinical Oncology	2003	252
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma John P. Leonard, Morton Coleman, Jamie Ketas, Clinical Cancer Research	2004	226
Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma John P. Leonard, Morton Coleman, Jamie Ketas, Journal of Clinical Oncology	2005	163
Epratuzumab: targeting B-cell malignancies through CD22. Morton Coleman, David M. Goldenberg, Abby B. Siegel, PubMed B-cell MalignanciesLymphoid NeoplasiaAntilymphoma ActivityAllergyMedicine	2003	47
Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results. John P. Leonard, Richard R. Furman, Ying‐Kuen Cheung, Blood	2005	41
Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease. Jia Ruan, Morton Coleman, Richard R. Furman, Blood	2006	12

Page 1